The cancer-immunity cycle provides a framework to understand the series of events that
generate anti-cancer immune responses. It emphasizes the iterative nature of the response …

Abstract Context The European Association of Urology (EAU) guidelines panel on upper
urinary tract urothelial carcinoma (UTUC) has updated the guidelines to aid clinicians in …

Background No new agent has improved overall survival in patients with unresectable or
metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy …

Background No treatment has surpassed platinum-based chemotherapy in improving
overall survival in patients with previously untreated locally advanced or metastatic …

Cuproptosis is a new cell death that depends on copper (Cu) ionophores to transport Cu into
cancer cells, which induces cell death. However, existing Cu ionophores are small …

Bladder cancer is a global health issue with sex differences in incidence and prognosis.
Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways …

Urothelial carcinoma (UC), also described as bladder cancer, is the 10th most common
cancer type worldwide, with an estimated 549 000 new cases and 200 000 deaths in 2018 …

Background Immunotherapy has determined unprecedented long-term responses in several
hematological and solid tumors. In the MOUSEION-03 study, we conducted a meta-analysis …

Context Treatment of metastatic urothelial carcinoma is currently undergoing a rapid
evolution. Objective This overview presents the updated European Association of Urology …

PURPOSE Cisplatin-based combination chemotherapy remains the standard of care for
locally advanced or metastatic urothelial cancer (la/mUC); however, toxicity is substantial …